Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1997 2
1999 12
2000 5
2001 4
2002 5
2003 2
2004 7
2005 2
2006 4
2007 4
2008 4
2009 5
2012 1
2020 0
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 10026068

58 results
Results by year
Filters applied: . Clear all
Page 1
Questions about palivizumab (Synagis).
Eppes SC. Eppes SC. Pediatrics. 1999 Feb;103(2):534-5; author reply 535-6. Pediatrics. 1999. PMID: 10026068 Clinical Trial. No abstract available.
Questions about palivizumab (Synagis).
Lee SL, Robinson JL. Lee SL, et al. Pediatrics. 1999 Feb;103(2):535; author reply 535-6. Pediatrics. 1999. PMID: 10026069 Clinical Trial. No abstract available.
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ, Malinoski FJ. Mahadevia PJ, et al. Arch Pediatr Adolesc Med. 2007 May;161(5):519-20; author reply 520. doi: 10.1001/archpedi.161.5.519. Arch Pediatr Adolesc Med. 2007. PMID: 17485634 No abstract available.
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003 Dec;112(6 Pt 1):1442-6. Pediatrics. 2003. PMID: 14654627
Comments on palivizumab (Synagis).
Moler FW, Brown RW, Faix RG, Gilsdorf JR. Moler FW, et al. Pediatrics. 1999 Feb;103(2):495-7. doi: 10.1542/peds.103.2.495. Pediatrics. 1999. PMID: 9925848 Clinical Trial. No abstract available.
Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
Robinson JL. Robinson JL. Curr Med Res Opin. 2009 Jul;25(7):1631-2; author reply 1632-3. doi: 10.1185/03007990902993415. Curr Med Res Opin. 2009. PMID: 19480611 No abstract available.
Palivizumab (Synagis) for prevention of RSV infection.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1999 Jan 1;41(1043):3-4. Med Lett Drugs Ther. 1999. PMID: 9924488 No abstract available.
58 results
Jump to page
Feedback